Advances in Targeted Therapy and Drugs for Advanced Colorectal Cancer

Abstract

Colorectal cancer (CRC) is one of the common malignant tumors of the digestive tract. Traditional conventional treatments primarily include surgery, chemotherapy, and radiotherapy. However, for advanced colorectal cancer, treatment often relies on drug rechallenge. Research on targeted therapy mainly focuses on molecular targets that inhibit tumor growth and proliferation. Anti-epidermal growth factor receptor (EGFR) drugs and anti-vascular endothelial growth factor (VEGF) drugs are options for treating advanced CRC. Some targeted drugs are already in clinical use, while others are undergoing clinical trials. In recent years, with advancements in molecular technology, an increasing number of biomarkers have been discovered. Targeted therapy has achieved significant success in the treatment of advanced CRC, leading to improved prognosis and quality of life for patients. This article summarizes the targeted pathways and drugs applied in the clinical treatment of rectal cancer in recent years, providing a reference for the precision treatment of advanced colorectal cancer.